39 related articles for article (PubMed ID: 2702642)
1. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Renaud EJ; MacLaughlin DT; Oliva E; Rueda BR; Donahoe PK
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):111-6. PubMed ID: 15618407
[TBL] [Abstract][Full Text] [Related]
2. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
3. The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.
Boesch M; Zeimet AG; Reimer D; Schmidt S; Gastl G; Parson W; Spoeck F; Hatina J; Wolf D; Sopper S
Oncotarget; 2014 Aug; 5(16):7027-39. PubMed ID: 25216521
[TBL] [Abstract][Full Text] [Related]
4. Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.
MacLaughlin DT; Donahoe PK
Future Oncol; 2010 Mar; 6(3):391-405. PubMed ID: 20222796
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Yamada N; Kato M; ten Dijke P; Yamashita H; Sampath TK; Heldin CH; Miyazono K; Funa K
Br J Cancer; 1996 Mar; 73(5):624-9. PubMed ID: 8605097
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical demonstration of the binding and internalization of growth hormone in GERL of Chang hepatoma cells.
Wang JJ; Chang JP; Teng CS
Cell Tissue Res; 1990 Nov; 262(2):273-81. PubMed ID: 2076535
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.
Wilson AP; Fox H; Scott IV; Lee H; Dent M; Golding PR
Br J Cancer; 1991 Jan; 63(1):102-8. PubMed ID: 1989647
[TBL] [Abstract][Full Text] [Related]
8. Embryology and classification of intersex states.
Josso N
Indian J Pediatr; 1992; 59(4):467-73. PubMed ID: 1452266
[No Abstract] [Full Text] [Related]
9. Genetic studies of MIS signalling in sexual development.
Jamin SP; Arango NA; Mishina Y; Behringer RR
Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
[TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance in reproduction and cancer.
Donahoe PK
Mol Reprod Dev; 1992 Jun; 32(2):168-72. PubMed ID: 1637555
[TBL] [Abstract][Full Text] [Related]
11. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK
Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323
[TBL] [Abstract][Full Text] [Related]
13. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
14. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]